Physician profile
Amy M Patrick
NPI 1861409518
$2,742.94
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,104 · 2020: $234 · 2021: $562 · 2022: $761 · 2023: $82.67.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $82.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $82.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,157.46 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.93 | 2019-2023 | Xifaxan, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $240.60 | 2019-2021 | |
| Pfizer INC. | $195.38 | 2019-2021 | |
| Janssen Biotech, INC. | $173.02 | 2019-2021 | |
| Qol Medical, LLC | $171.22 | 2019-2020 | |
| Celgene Corporation | $105.77 | 2021-2023 | Zeposia |
| Ironwood Pharmaceuticals, INC | $62.29 | 2019-2022 | |
| Shire North American Group INC | $45.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $43.05 | 2019 | |
| Biofire Diagnostics, LLC | $37.68 | 2019 | |
| Gilead Sciences, INC. | $35.80 | 2019 | |
| Boston Scientific Corporation | $22.66 | 2019 | |
| Merck Sharp & Dohme LLC | $17.52 | 2019 | |
| Covidien LP | $16.06 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endogastric Solutions, INC | $9.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.